References
- Organization WH. WHO coronavirus (COVID-19) dashboard. Geneva: WHO; 2023. https://covid19.who.int/?adgroupsurvey=.
- Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608(7923):603–8. doi:10.1038/s41586-022-05053-w.
- China CPsGotPsRo. The latest situation of coronavirus disease 2019 (COVID-19) as of 24: 00 on December 23. Health Commission of The People’s Republic Of China; 2022. https://www.gov.cn/xinwen/2022-12/24/content_5733356.htm.
- The low proportion of severe cases in this round of COVID-19 is mainly manifested by the aggravation of underlying diseases. 2022. https://news.cctv.com/2022/12/06/ARTIwRq3t7CKO3p3Z129QqD6221206.shtml.
- Wang B, Yu Y, Yu Y, Wang N, Chen F, Jiang B, Chen Y, Zhang J, Liu J, Wang H, et al. Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China. J Infect. 2023;86(1):e27–e9. doi:10.1016/j.jinf.2022.08.001.
- China CPsGotPsRo. Continue to improve the scientific precision level of prevention and control – interpretation of the “new Ten points” in the press conference of the joint prevention and control mechanism of the state council. The Xinhua News Agency; 2022. http://www.gov.cn/zhengce/2022-12/08/content_5730631.htm.
- China CPsGotPsRo. The joint prevention and control mechanism of the state council announced 20 measures to further optimize epidemic prevention and control. The Xinhua News Agency; 2022. http://www.gov.cn/xinwen/2022-11/11/content_5726144.htm.
- Yang H, Xie Y, Li C. Understanding the mechanisms for COVID-19 vaccine’s protection against infection and severe disease. Expert Rev Vaccines. 2023;22(1):186–92. doi:10.1080/14760584.2023.2174529.
- Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, Al-Khatib HA, Smatti MK, Coyle P, Al-Kanaani Z, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med. 2022;387(1):21–34. doi:10.1056/NEJMoa2203965.
- Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, Ren J, Li Z, Guo X, Tao F, et al. Effectiveness of inactivated and Ad5-nCov COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. BMC Med. 2022;20(1):400. doi:10.1186/s12916-022-02606-8.
- Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O’Brien KL, Smith PG, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–44. doi:10.1016/S0140-6736(22)00152-0.
- Daily B. Beijing’s COVID-19 vaccination schedule. Beijing Daily; 2020. https://baijiahao.baidu.com/s?id=1687588668205882292&wfr=spider&for=pc.
- On July 20, Beijing launched a full vaccination campaign against the novel coronavirus for people aged 12 to 17. People’s Information. https://baijiahao.baidu.com/s?id=1705874331349428384&wfr=spider&for=pc.
- Vaccination time of COVID-19 booster vaccine in Beijing. Beijing local treasure. 2021. https://emkycu.smartapps.cn/pages/article/detail/detail?id=301742&city=bj&type=article&_um_ssrc=SwqWU4PQbCXgTyptFbRto2r6VhHUngw64Rj7C1Eey1kaHUrVckk8eLaZw9JxuQ6eTaMbUNPKpKYEBznEzkuJKFXKW&_um_sts=1696844208766&_swebfr=1&_swebFromHost=heytapbrowser.
- Feng Jun GY, Yanni Y, Dayong Z, Li Z. Research on the accessibility of vaccination outpatient service based on geographic information system. Chin Health Ser Manage. 2017;10:792–5.
- Baike B. China disease control weekly report: from December 2022 to February 2023, more than 80% of the country’s population has been infected with the novel coronavirus. 2023. https://baijiahao.baidu.com/s?id=1764419103459284659&wfr=spider&for=pc.
- Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W. Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: a systematic review. EClinicalMedicine. 2021;40:101113. doi:10.1016/j.eclinm.2021.101113.
- Beijing tCfDCaPo. Information disclosure of booster vaccination sites of SARS-CoV-2 vaccine. The Center For Disease Control And Prevention of Beijing; 2022. https://www.bjcdc.org/article/69021/2021/10/1634685869733.html.
- Statistics BMBo. Beijing regional statistical yearbook. 2022. https://nj.tjj.beijing.gov.cn/nj/qxnj/2022/zk/indexch.htm.
- Ye, Lixia, Fang, Ting, Ma, Rui, Zhu, Guanghui, Dong, Hongjun. Investigation on human resources of adult vaccination clinic in Ningbo city. Prev Med. 2017;29:750–3.
- Parihari S, Das Chatterjee N, Das K, Bhattacharya RK. Chapter 4 - role of groundwater potentiality and soil nutrient status on agricultural productivity: a case study in Paschim Medinipur district, West Bengal. In: Shit P; Bhunia G, and Adhikary P editors. Case studies in geospatial applications to groundwater resources. India: Elsevier; 2023. p. 39–66. doi:10.1016/B978-0-323-99963-2.00008-0.
- Ripley BD. Tests of’randomness’ for spatial point patterns. J Royal Stat Soc. 1979;41(3):368–74. doi:10.1111/j.2517-6161.1979.tb01091.x.
- Staples JN, Nelamangala SL, Morris S, Wells K. Exploring socio-demographic and geospatial variation in human papillomavirus vaccination uptake in Virginia. Vaccine. 2021;39(38):5385–90. doi:10.1016/j.vaccine.2021.07.079.
- xinhuanet. Vaccination in the elderly can effectively prevent severe disease and death of COVID-19. xinhuanet; 2022. http://www.news.cn/politics/2022-07/23/c_1128856228.htm.
- Whitaker M, Elliott J, Bodinier B, Barclay W, Ward H, Cooke G, Donnelly CA, Chadeau-Hyam M, Elliott P. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat Commun. 2022;13(1):6856. doi:10.1038/s41467-022-34244-2.
- W DB. Ten grassroots health institutions explore: family doctors will prescribe adult vaccines. Southern Urban Daily; 2023. https://www.sohu.com/a/677777881_161795.
- Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, et al. A bivalent Omicron-containing booster vaccine against COVID-19. N Engl J Med. 2022;387(14):1279–91. doi:10.1056/NEJMoa2208343.
- Deng W, Lv Q, Li F, Liu J, Song Z, Qi F, Wei Q, Yu P, Liu M, Zhou S, et al. Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in rhesus macaques. Sig Trans Targeted Ther. 2022;7(1):124. doi:10.1038/s41392-022-00979-z.
- Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, Zhu T, Zhang J, Luo L, Fan P, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCov) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021;21(12):1654–64. doi:10.1016/S1473-3099(21)00396-0.
- Xu F, Wu S, Yi L, Peng S, Wang F, Si W, Hou L, Zhu T. Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques. Emerg Microbes Infect. 2022;11(1):438–41. doi:10.1080/22221751.2022.2030199.